Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection

JAMA Pediatrics

Volumn 169, Issue 4, 2015, Pages 341-348

  Gutfraind, Alexander ^a,b   Galvani, Alison P ^c   Meyers, Lauren Ancel ^d,e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e SANTA FE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ARTICLE; DISEASE SURVEILLANCE; DRUG COST; DRUG EFFICACY; HOSPITALIZATION; HUMAN; INFECTION RISK; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK REDUCTION; SEASONAL VARIATION; UNITED STATES; BLOOD; ECONOMICS; EVALUATION STUDY; HEALTH SURVEY; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNIZATION; IMMUNOLOGY; INFANT; PREMATURITY; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; DRUG COSTS; HOSPITALIZATION; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, PREMATURE; MODELS, THEORETICAL; PALIVIZUMAB; POPULATION SURVEILLANCE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; UNITED STATES;

EID: 84928252295     PISSN: 21686203     EISSN: 21686211     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2014.3804     Document Type: Article

References (36)

1. Thompson WW, Shay DK,Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289(2):179-186
2. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics. 2004;114(6):1612-1619
3. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-1555. doi:10.1016/S0140-6736 (10)60206-1
4. Resch B. Burden of respiratory syncytial virus infection in young children.World J Clin Pediatr. 2012;1(3):8-12. doi:10.5409/wjcp.v1.i3.8
5. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531-537
6. Fenton C, Scott LJ, Plosker GL. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs. 2004;6(3):177-197
7. Morris SK, Dzolganovski B, Beyene J, Sung L. Ameta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis. 2009;9(1):106. doi:10.1186/1471-2334-9-106
8. Johansson L, Soriot P. Annual report. AstraZeneca website. http://www.astrazeneca-annualreports.com/2012/documents/eng-download-centre/annual-report.pdf. Accessed October 4, 2013
9. Simoes EAF, Groothuis JR. Respiratory syncytial virus prophylaxis: the story so far. Respir Med. 2002; 96(suppl B):S15-S24. doi:10.1053/rmed.2002.1296
10. Saez-Llorens X, Moreno MT, Ramilo O, Sanchez PJ, Top FH Jr, Connor EM; MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004; 23(8):707-712
11. Pickering LK, Baker CJ, Kimberlin DW, Long SS; Committee on Infectious Diseases. Red Book: 2014 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2014
12. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3, pt 1):419-427
13. Meissner HC, Kimberlin DW. RSV immunoprophylaxis: does the benefit justify the cost? Pediatrics. 2013;132(5):915-918
14. Hampp C, Saidi AS,Winterstein AG. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr. 2010;156(6):953-959.e1. doi:10.1016/j.jpeds .2009.12.016
15. Storey S. Respiratory syncytial virus market. Nat Rev Drug Discov. 2010;9(1):15-16
16. State of Texas Health and Human Services Commission. Top 100 drugs by expenditure in SFY 2011 second quarter. 2011. http://www .txvendordrug.com. Accessed August 20, 2012
17. Panozzo CA, Stockman LJ, Curns AT, Anderson LJ. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis. Pediatrics. 2010;126(1):e116-e123
18. Mullins JA, Lamonte AC, Bresee JS, Anderson LJ. Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J. 2003;22(10):857-862
19. Panozzo CA, Fowlkes AL, Anderson LJ. Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance. Pediatr Infect Dis J. 2007;26(11)(suppl):S41-S45
20. Mutuc JD, Langley GE; Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus-United States, July 2007-June 2011. MMWR Morb Mortal Wkly Rep. 2011;60(35):1203-1206
21. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701
22. Pickering LK; Committee on Infectious Diseases. Red Book: 2012 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2012
23. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997; 176(5):1215-1224
24. Zaaijer HL, Vandenbroucke-Grauls CM, Franssen EJ. Optimum dosage regimen of palivizumab? Ther Drug Monit. 2002;24(3):444-445
25. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620-e638. doi:10.1542/peds.2014-1666
26. Guyon I, Elisseef A. An introduction to variable and feature selection. J Mach Learn Res. 2003;3: 1157-1182
27. LeecasterM, Gesteland P, Greene T, et al. Modeling the variations in pediatric respiratory syncytial virus seasonal epidemics. BMC Infect Dis. 2011;11(1):105. doi:10.1186/1471-2334-11-105
28. Hampp C, Kauf TL, Saidi AS,Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165(6):498-505
29. Mahadevia PJ, Masaquel AS, Polak MJ,Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. JMed Econ. 2012;15(5):987-996
30. Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ. 2012;15 (5):997-1018
31. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008;12(36):3; 9-10; 1-86
32. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56(9): 4927-4936
33. La ViaWV, Notario GF, Yu X-Q, Sharma S, Noertersheuser PA, Robbie GJ. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther. 2013;26(6):666-671
34. Hall CB,Walsh EE, Schnabel KC, et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis. 1990;162(6):1283-1290
35. Light M, Bauman J, Mavunda K, Malinoski F, EgglestonM. Correlation between respiratory syncytial virus (RSV) test data and hospitalization of children for RSV lower respiratory tract illness in Florida. Pediatr Infect Dis J. 2008;27(6):512-518
36. Zachariah P, Shah S, Gao D, Simoes EAF. Predictors of the duration of the respiratory syncytial virus season. Pediatr Infect Dis J. 2009;28 (9):772-776.